physiolog
condit
blood
glucos
tightli
regul
number
mechan
includ
incretin
system
hormon
secret
respons
meal
glucagon
like
peptid
gastrointestin
peptid
gip
releas
gut
regul
postprandi
glucos
excurs
proglucagon
secret
intestin
mucosa
subsequ
cleav
act
receptor
pancrea
glucosedepend
manner
function
stimul
pancreat
insulin
releas
suppress
glucagon
secret
net
effect
regul
postprandi
glucos
halflif
short
minut
rapidli
degrad
dipeptidylpeptidas
cleav
two
amino
acid
amino
termin
end
peptid
prolin
less
commonli
alanin
penultim
posit
henc
amid
cleav
amid
major
circul
form
insulinotrop
effect
dipeptidyl
peptidas
inhibitor
novel
oral
diabet
agent
use
lower
blood
glucos
patient
type
diabet
mellitu
inhibit
degrad
result
rais
endogen
promot
insulin
releas
inhibit
glucagon
secret
caus
lower
blood
glucos
favor
aspect
comparison
diabet
agent
includ
oral
formul
reduc
risk
hypoglycemia
lack
weight
gain
addit
benefit
beyond
glucos
lower
cleav
host
peptidessubstr
addit
result
broad
rang
alter
biolog
function
review
focu
pleiotrop
properti
beyond
glucos
lower
specif
refer
renoprotect
cardiovascular
aspect
summar
figur
clinic
relev
fact
third
patient
diabet
suffer
renal
complic
main
caus
mortal
cardiovascular
origin
henc
continu
inquiri
mechan
renal
failur
patient
diabet
lead
examin
novel
strategi
limit
cardiovascular
renal
diseas
logic
step
forward
type
integr
membran
glycoprotein
express
ubiquit
organ
cell
type
exist
solubl
membran
bound
form
capabl
proteolyt
activ
solubl
form
circul
thought
aris
shed
membran
bound
target
hypoglycem
agent
clinic
use
identifi
substrat
includ
regul
activ
normal
cell
express
secret
rant
relev
renal
diseas
brain
natriuret
peptid
neuropeptid
high
mobil
group
protein
substanc
p
recent
aggreg
amyloid
beta
peptid
patholog
hallmark
alzheim
diseas
also
identifi
substrat
mani
substrat
identifi
pharmacolog
substrat
cleav
vitro
cleav
vivo
henc
proteolyt
effect
either
lead
gain
function
loss
function
function
signific
exampl
physiolog
relev
substrat
highlight
truncat
certain
chemokin
colonystimul
factor
interleukin
recent
link
regul
hematopoiet
stemprogenitor
cell
shown
enhanc
engraft
cord
blood
patient
hematolog
malign
membran
bound
form
express
surfac
mani
cell
type
includ
kidney
tubular
cell
endotheli
cell
cell
major
interest
respect
pleiotrop
action
membranebound
also
exert
nonenzymat
action
virtu
coloc
membran
protein
modul
intrins
action
known
interact
adenosin
deaminas
caveolin
cation
independ
mannos
phosphat
receptor
also
known
insulin
growth
factor
receptor
glypican
interestingli
recogn
interact
human
coronavirusemc
spike
protein
act
receptor
viru
provid
new
knowledg
facilit
direct
intervent
strategi
relat
respiratori
ill
proteolyt
function
kidney
describ
use
liquid
chromatographi
mass
spectrometrybas
peptidom
kidney
tissu
mice
compar
reveal
peptid
regul
vivo
studi
brush
border
membran
show
aminopeptidas
activ
requir
gener
substrat
suggest
involv
extracellular
catabol
protein
kidney
specif
degradationcatabol
prolinecontain
peptid
present
brush
border
apic
side
kidney
proxim
tubular
cell
inhibit
like
alter
degradationregul
peptid
lumen
thu
influenc
tubular
cell
structur
function
diabet
identifi
function
relev
renal
substrat
help
us
understand
anticip
longterm
effect
inhibit
kidney
patient
diabet
tool
requir
valid
identifi
substrat
limit
given
specif
antibodi
must
abl
distinguish
cleav
noncleav
peptid
differ
two
amino
acid
ntermin
end
transform
growth
factor
beta
major
driver
fibrosi
diabet
kidney
diseas
report
linagliptin
reduc
high
glucoseinduc
activ
human
kidney
proxim
tubular
cell
downstream
reduct
phosphoryl
fibronectin
transcript
express
highglucoseinduc
total
secret
unchang
linagliptin
postul
mechan
relat
interfer
convers
latent
activ
secret
latent
form
requir
complex
interplay
solubl
signal
molecul
activ
process
releas
latenc
associ
peptid
lap
releas
lap
unbound
bind
receptor
initi
cell
signal
via
smad
pathway
pursu
show
interact
switch
high
glucos
henc
maxim
modul
linagliptin
environ
presenc
excess
bind
site
becom
satur
result
reduct
interact
would
impli
interact
occur
residu
molecul
fact
linagliptin
also
reduc
interact
suggest
mechan
independ
vitro
system
lack
unpublish
data
novel
find
add
bodi
knowledg
inhibit
exert
antifibrot
effect
nonproteolyt
properti
discuss
respect
endotheli
cell
dysfunct
interpret
preclin
studi
import
appreci
confound
aspect
concomit
glucos
lower
two
studi
look
effect
use
vildagliptin
sitagliptin
diabet
anim
kidney
show
renoprotect
howev
hemoglobin
diabet
anim
lower
diabeticcontrol
anim
vivo
studi
difficult
conclud
renal
effect
lie
beyond
glucos
lower
kanasaki
colleagu
investig
antifibrot
properti
linagliptin
type
model
diabet
nephropathi
show
week
linagliptin
amelior
diabet
kidney
fibrosi
observ
occur
associ
inhibit
endothelialmesenchym
transit
endmt
restor
insulindefici
model
diabet
enabl
evalu
effect
independ
glycem
control
signific
hypoglycem
effect
due
lack
signific
insulin
respons
mediat
result
new
find
provid
inform
regard
renal
benefit
linagliptin
independ
glycem
control
antifibrot
properti
also
shown
model
kidney
fibrosi
unilater
ureter
obstruct
uuo
model
model
reduc
inflammatori
fibrot
marker
level
phosphoryl
tolllik
receptor
nadph
oxidas
nuclear
factor
kappa
b
howev
studi
lack
specif
mechanist
data
explain
find
also
experiment
evid
suggest
involv
advanc
glycat
end
product
receptor
axi
highli
relev
diabet
kidney
diseas
defici
linagliptin
reduc
renal
damag
anim
model
type
diabet
nephropathi
mechan
propos
relat
reduc
endotheli
cell
oxid
stress
likewis
explor
anim
model
obes
insulin
resist
renal
diseas
shown
reduc
obesityinduc
renal
injuri
attenu
filtrat
barrier
injuri
oxid
stress
zucker
obes
rat
linagliptin
endotheli
dysfunct
inher
aspect
diabet
kidney
diseas
shi
et
al
demonstr
endotheli
cell
integrin
physic
interact
endotheli
mesenchym
transit
inhibit
integrin
delet
addit
integrin
defici
result
inhibit
heterodim
format
receptor
along
interact
integrin
induc
vascular
endotheli
growth
factor
receptor
vegfr
express
concomit
suppress
level
importantli
linagliptin
abl
reduc
physic
interact
integrin
result
indic
nonproteolyt
interact
integrin
relev
diabet
kidney
fibrosi
mechanist
studi
design
delin
whether
effect
glucoseinduc
endotheli
impair
relat
independ
show
addit
receptor
effect
linagliptin
exert
direct
effect
rat
mesenter
vessel
independ
glucos
lower
effect
mechan
shown
relat
antioxid
effect
direct
radic
scaveng
inhibitor
also
exert
antiinflammatori
effect
demonstr
nondiabet
anim
model
glomerular
injuri
alogliptin
reduc
macrophag
infiltr
likewis
type
diabet
nephropathi
model
reduc
macrophag
infiltr
nuclear
factor
kappa
b
activ
increasingli
evid
although
similar
capac
improv
glucos
control
differ
pharmacokinet
pharmacodynam
profil
bind
differ
site
inhibitor
block
enzymat
ie
cleav
properti
may
differ
abil
influenc
costimulatoryreceptor
properti
mode
clearanc
inhibitor
may
also
relev
highli
express
lumin
aspect
proxim
tubular
brush
border
impli
drug
preferenti
filter
kidney
better
access
tubular
summari
preclin
studi
suggest
offer
renoprotect
beyond
glucos
lower
proteolyt
proteinprotein
interact
antioxid
properti
given
increas
cardiovascular
risk
popul
would
highli
desir
glucoselow
drug
also
offer
cardiovascular
benefit
addit
renoprotect
regulatori
agenc
mandat
new
diabet
agent
undergo
cardiovascular
assess
prior
market
agreedon
primari
endpoint
cardiovascular
safeti
analys
major
advers
cardiovascular
event
plu
maceplu
defin
composit
endpoint
consist
follow
adjud
event
cardiovascular
death
nonfat
myocardi
infarct
nonfat
stroke
hospit
unstabl
angina
next
section
summar
major
clinic
trial
area
cardiovascular
renal
endpoint
clinic
trial
evalu
cardiovascular
renal
endpoint
commenc
carmelina
studi
includ
adult
type
diabet
linagliptin
clinicaltrialsgov
identifi
primari
endpoint
time
first
occurr
either
cardiovascular
death
includ
fatal
stroke
fatal
myocardi
infarct
nonfat
myocardi
infarct
nonfat
stroke
hospit
unstabl
angina
pectori
renal
outcom
measur
composit
renal
death
sustain
endstag
renal
diseas
sustain
decreas
egfr
although
offer
promis
preclin
studi
post
hoc
analys
clinic
trial
suggest
posit
cardiovascular
risk
profil
recent
random
placebo
control
trial
savortimi
publish
new
england
journal
medicin
scirica
et
al
show
chang
ischem
event
higher
hospit
heart
failur
saxagliptin
studi
enrol
patient
type
diabet
histori
risk
cardiovascular
event
follow
median
year
examin
studi
evalu
alogliptin
use
patient
type
diabet
acut
coronari
syndrom
show
increas
rate
maceplu
random
placebocontrol
trial
involv
patient
median
follow
month
us
food
drug
administr
fda
independ
advisori
committe
recent
vote
cardiovascular
safeti
profil
two
drug
could
manag
updat
drug
label
recent
larg
multicentr
clinic
trial
teco
sitagliptin
cardiovascular
outcom
studi
patient
establish
cardiovascular
diseas
type
diabet
random
receiv
either
saxagliptin
placebo
addit
usual
therapi
show
increas
risk
maceplu
hospit
heart
failur
advers
event
anoth
larg
multicentr
trial
linagliptin
carolina
cardiovascular
outcom
studi
linagliptin
versu
glimepirid
patient
type
diabet
current
progress
rais
also
import
take
account
cardiovascular
profil
analog
larg
retrospect
analysi
best
et
al
patient
treat
analog
exenatid
shown
reduct
cardiovascular
event
comparison
glucoselow
agent
howev
studi
demonstr
cardiovascular
benefit
use
analog
use
supra
physiolog
dose
promot
action
within
physiolog
rang
like
pleiotrop
effect
independ
effect
outlin
detail
trial
found
wwwclinitrialsgov
sever
inhibitor
clinic
use
eg
sitagliptin
saxagliptin
vildagliptin
alogliptin
linagliptin
differ
structur
pharmacokinet
profil
henc
outcom
ongo
trial
import
class
effect
presum
conclus
inhibitor
hold
promis
antifibrot
antiinflammatori
agent
kidney
diseas
larg
clinic
trial
current
underway
evalu
hard
renal
endpoint
juri
still
whether
risk
heart
failur
class
effect
